Real-world data on Nuvaxovid adverse events are in
The first information on Australian patients’ experiences of the new COVID-19 shot shows how its safety profile differs from other vaccines
The first safety data for Novavax’s COVID-19 vaccine have been analysed and show more cases of fatigue and headache than after Comirnaty but fewer injection-site reactions.
More than 35,000 doses of the protein subunit vaccine, Nuvaxovid, have gone into arms since it received TGA and ATAGI approval in January.
The Federal Government has estimated that between 45,000 and 180,000 Australians were “waiting for Novavax” because of their safety concerns about both mRNA COVID-19 vaccines and AstraZeneca’s vaccine, Vaxzevria.
Of the first 867 patients surveyed about adverse events after the new vaccine, 38% reported at least one — most commonly fatigue (28%) — followed by injection-site reactions (24%), headache (22%) and muscle pain (19%).
